Response to Comments: Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers

This article documents responses to public comments on the existing policy for skin substitute grafts/cellular and tissue‑based products (CTPs) for diabetic foot ulcers and venous leg ulcers but does not itself establish new coverage or exclusion determinations. It states that all comments were reviewed and addressed (some combined or cross‑referenced); refer to the underlying coverage policy for specific covered services and clinical requirements.